Biocept (NASDAQ:BIOC) announced its earnings results on Wednesday. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.10), MarketWatch Earnings reports. Biocept had a negative return on equity of 268.76% and a negative net margin of 552.54%.
Shares of NASDAQ:BIOC opened at $0.35 on Thursday. The stock has a market capitalization of $28.85 million, a P/E ratio of -0.13 and a beta of -0.89. The stock’s 50-day moving average price is $0.37 and its 200-day moving average price is $0.51. The company has a current ratio of 1.83, a quick ratio of 1.71 and a debt-to-equity ratio of 0.13. Biocept has a 12-month low of $0.21 and a 12-month high of $2.11.
Separately, Maxim Group restated a “buy” rating and set a $1.00 price target on shares of Biocept in a research report on Friday, March 6th.
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Featured Story: Diversification For Individual Investors
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.